{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:34:46Z","timestamp":1793676886219,"version":"4.5.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In PREDIX LumB patients with estrogen receptor positive and human epidermal growth factor receptor negative (ER\u2009+\u2009\/HER2-) breast cancer &gt; 20\u2009mm and\/or with lymph node metastasis were randomized 1:1 to receive either paclitaxel weekly for 12 weeks followed by palbociclib and endocrine therapy for 12 weeks (arm A), or the reverse sequence (arm B). Primary endpoint is objective radiologic response at 12 weeks (ORR\n                    <jats:sub>12<\/jats:sub>\n                    ), and key secondary endpoints are ORR\n                    <jats:sub>24<\/jats:sub>\n                    , pathologic complete response, event-free survival, safety and correlative studies of tissue and circulating biomarkers. Whole exome sequencing and RNA sequencing were performed on baseline fresh frozen tissue samples. In total, 179 patients comprise the intention-to-treat population. There is no statistically significant difference between the two arms in ORR\n                    <jats:sub>12<\/jats:sub>\n                    (59% vs 45%, p\u2009=\u20090.058). An exploratory gene expression analysis identified differentially expressed genes and gene sets between responders and non-responders at 12 weeks. A predictive signature, CDKPredX, comprising 31 genes related to proliferation, ER signaling and immune activity was developed to identify patients resistant to chemotherapy but responding to palbociclib plus endocrine therapy (p\n                    <jats:sub>interaction<\/jats:sub>\n                    =0.03). The predictive signature was independently validated in the CORALLEEN trial (p\n                    <jats:sub>interaction<\/jats:sub>\n                    =0.048). Clinicaltrials.gov identifier: NCT02603679\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71452-6","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:49:18Z","timestamp":1775648958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER\u2009+\u2009\/HER2- breast cancer: a randomized phase II trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-9624","authenticated-orcid":false,"given":"Alexios","family":"Matikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Tzoras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Sarafidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-4471","authenticated-orcid":false,"given":"Emmanouil G.","family":"Sifakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bj\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Barnekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Isaksson-Friman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Edman","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-827X","authenticated-orcid":false,"given":"Athanasios","family":"Zouzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Agartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1141-6234","authenticated-orcid":false,"given":"Per","family":"Gryb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3020-0359","authenticated-orcid":false,"given":"Dimitrios","family":"Salgkamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-2462","authenticated-orcid":false,"given":"Ioannis","family":"Zerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-1803","authenticated-orcid":false,"given":"Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-8527","authenticated-orcid":false,"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4633","authenticated-orcid":false,"given":"Balazs","family":"Acs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Boyaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"Tomas","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Gavila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Perou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Brandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-1847","authenticated-orcid":false,"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hatschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-9987","authenticated-orcid":false,"given":"Theodoros","family":"Foukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"71452_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 32, 1475\u20131495 (2021).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"71452_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi, P. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 42, 987\u2013993 (2024).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"71452_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D. et al. Ribociclib plus Endocrine therapy in early breast cancer.  N. Engl. J. Med. 390, 1080\u20131091 (2024).","journal-title":"N. Engl. J. Med."},{"key":"71452_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10238-022-00814-3","volume":"23","author":"Y Guan","year":"2023","unstructured":"Guan, Y. et al. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis. Clin. Exp. Med. 23, 245\u2013254 (2023).","journal-title":"Clin. Exp. Med"},{"key":"71452_CR5","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00625-7","volume":"10","author":"T Pascual","year":"2024","unstructured":"Pascual, T. et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ Breast Cancer 10, 20 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"71452_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 21, 33\u201343 (2020).","journal-title":"Lancet Oncol."},{"key":"71452_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejso.2018.09.027","volume":"45","author":"PER Spronk","year":"2019","unstructured":"Spronk, P. E. R., Volders, J. H., van den Tol, P., Smorenburg, C. H. & Vrancken Peeters, M. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit. Eur. J. Surg. Oncol. 45, 110\u2013117 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"71452_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart, L. L. et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv. Ther. 38, 350\u2013365 (2021).","journal-title":"Adv. Ther."},{"key":"71452_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-21-2272","volume":"28","author":"AR Tan","year":"2022","unstructured":"Tan, A. R. et al. Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study. Clin. Cancer Res. 28, 629\u2013636 (2022).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero, B. et al. CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell 37, 340\u201353 e6 (2020).","journal-title":"Cancer Cell"},{"key":"71452_CR12","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-18-0790","volume":"25","author":"AS Clark","year":"2019","unstructured":"Clark, A. S. et al. Combination paclitaxel and palbociclib: results of a phase I trial in advanced breast cancer. Clin. Cancer Res. 25, 2072\u20132079 (2019).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12149-018-01323-8","volume":"33","author":"S Taralli","year":"2019","unstructured":"Taralli, S. et al. Response evaluation with (18)F-FDG PET\/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice. Ann. Nucl. Med 33, 193\u2013200 (2019).","journal-title":"Ann. Nucl. Med"},{"key":"71452_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1193174","volume":"13","author":"A Annovazzi","year":"2023","unstructured":"Annovazzi, A. et al. Prognostic value of [18F]-FDG PET\/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors. Front Oncol. 13, 1193174 (2023).","journal-title":"Front Oncol."},{"key":"71452_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/bjc.2017.446","volume":"118","author":"T Foukakis","year":"2018","unstructured":"Foukakis, T. et al. Immune gene expression and response to chemotherapy in advanced breast cancer. Br. J. Cancer 118, 480\u2013488 (2018).","journal-title":"Br. J. Cancer"},{"key":"71452_CR16","doi-asserted-by":"publisher","first-page":"e1466017","DOI":"10.1080\/2162402X.2018.1466017","volume":"7","author":"A Matikas","year":"2018","unstructured":"Matikas, A. et al. Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. Oncoimmunology 7, e1466017 (2018).","journal-title":"Oncoimmunology"},{"key":"71452_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.20.00853","volume":"39","author":"R Buus","year":"2021","unstructured":"Buus, R. et al. Molecular drivers of Oncotype DX, Prosigna, EndoPredict, and the breast cancer index: a TransATAC study. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 39, 126\u2013135 (2021).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"71452_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/1878-0261.12654","volume":"14","author":"I Zerdes","year":"2020","unstructured":"Zerdes, I. et al. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. Mol. Oncol. 14, 951\u2013963 (2020).","journal-title":"Mol. Oncol."},{"key":"71452_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(-) breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med"},{"key":"71452_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med"},{"key":"71452_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"EBCTCG, Peto, R. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432\u2013444 (2012).","journal-title":"Lancet"},{"key":"71452_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"34","author":"F Andre","year":"2023","unstructured":"Andre, F. et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 34, 1003\u20131014 (2023).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"71452_CR23","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1158\/1078-0432.CCR-22-3573","volume":"30","author":"MP Goetz","year":"2024","unstructured":"Goetz, M. P. et al. Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clin. Cancer Res. 30, 2233\u20132244 (2024).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR24","doi-asserted-by":"crossref","unstructured":"Stover D., et al. Abstract GS03-07: protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: genomic subtype derived from RNA sequencing of HR+\/HER2-early breast cancer. Cancer Res. 84, GS03-7-GS-7 (2024).","DOI":"10.1158\/1538-7445.SABCS23-GS03-07"},{"key":"71452_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","volume":"36","author":"LA Huppert","year":"2025","unstructured":"Huppert, L. A. et al. Pathologic complete response (pCR) rates for patients with HR+\/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 36, 172\u2013184 (2025).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"71452_CR26","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","volume":"55","author":"X Jin","year":"2023","unstructured":"Jin, X. et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat. Genet 55, 1696\u20131708 (2023).","journal-title":"Nat. Genet"},{"key":"71452_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40, 609\u2013623 e6 (2022).","journal-title":"Cancer Cell"},{"key":"71452_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccell.2025.01.002","volume":"43","author":"C Denkert","year":"2025","unstructured":"Denkert, C. et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. Cancer Cell 43, 232\u201347 e4 (2025).","journal-title":"Cancer Cell"},{"key":"71452_CR29","unstructured":"Loibl, S., et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up(dagger). Annals of oncology: official journal of the European Society for Medical Oncology (2023)."},{"key":"71452_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer. Clin. Cancer Res. 26, 566\u2013580 (2020).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1078-0432.CCR-21-1628","volume":"28","author":"M Dowsett","year":"2022","unstructured":"Dowsett, M. et al. Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER(+)\/HER2(-) breast cancer. Clin. Cancer Res. 28, 163\u2013174 (2022).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR32","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher, D. et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340, c869 (2010).","journal-title":"BMJ"},{"key":"71452_CR33","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 97, 1180\u20131184 (2005).","journal-title":"J. Natl. Cancer Inst."},{"key":"71452_CR34","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers, M. A. et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 14, 2756\u20132768 (1996).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"71452_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"71452_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans, W. F. et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 35, 1049\u20131060 (2017).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"71452_CR37","doi-asserted-by":"crossref","unstructured":"Litton J. K., et al. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J. Am. Soc. Clin. Oncol.41, 4433\u20134442 (2023).","DOI":"10.1200\/JCO.23.00435"},{"key":"71452_CR38","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1080\/0284186X.2023.2271165","volume":"62","author":"H Johansson","year":"2023","unstructured":"Johansson, H., Lagergren, P., Nolte, S. & Brandberg, Y. Comparison between Swedish EORTC QLQ-C30 general population norm data published in 2000 and 2019. Acta oncologica 62, 1592\u20131598 (2023).","journal-title":"Acta oncologica"},{"key":"71452_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"71452_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"71452_CR41","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-21-0325","volume":"27","author":"Y Bai","year":"2021","unstructured":"Bai, Y. et al. An open-source, automated tumor-infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer. Clin. Cancer Res. 27, 5557\u20135565 (2021).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1078-0432.CCR-22-2829","volume":"29","author":"A Matikas","year":"2023","unstructured":"Matikas, A. et al. Survival outcomes, digital TILs, and on-treatment PET\/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial. Clin. Cancer Res. 29, 532\u2013540 (2023).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR43","doi-asserted-by":"crossref","unstructured":"Boyaci, C., Sun, W., Robertson, S., Acs, B., Hartman, J. Independent clinical validation of the automated Ki67 scoring guideline from the international Ki67 in breast cancer working group. Biomolecules 11, 1612 (2021).","DOI":"10.3390\/biom11111612"},{"key":"71452_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41374-018-0123-7","volume":"99","author":"B Acs","year":"2019","unstructured":"Acs, B. et al. Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. Lab Invest 99, 107\u2013117 (2019).","journal-title":"Lab Invest"},{"key":"71452_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100076","volume":"6","author":"A Matikas","year":"2021","unstructured":"Matikas, A. et al. Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer. ESMO Open 6, 100076 (2021).","journal-title":"ESMO Open"},{"key":"71452_CR46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41379-022-01104-9","volume":"35","author":"B Acs","year":"2022","unstructured":"Acs, B. et al. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Mod. Pathol. 35, 1362\u20131369 (2022).","journal-title":"Mod. Pathol."},{"key":"71452_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.12688\/f1000research.16665.2","volume":"9","author":"M Garcia","year":"2020","unstructured":"Garcia, M. et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res. 9, 63 (2020).","journal-title":"F1000Res"},{"key":"71452_CR48","doi-asserted-by":"crossref","unstructured":"Vasimuddin, M., Misra, S., Li, H., Aluru, S. Efficient Architecture-Aware Acceleration of BWA-MEM for Multicore Systems. 2019 IEEE International Parallel and Distributed Processing Symposium (IPDPS); 314\u2013324 (2019).","DOI":"10.1109\/IPDPS.2019.00041"},{"key":"71452_CR49","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"71452_CR50","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"71452_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"71452_CR52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. (Austin) 6, 80\u201392 (2012).","journal-title":"Fly. (Austin)"},{"key":"71452_CR53","doi-asserted-by":"publisher","unstructured":"Kandoth C., et al. mskcc\/vcf2maf: vcf2maf v1.6.16 (v1.6.16). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.1185418 (2018).","DOI":"10.5281\/zenodo.1185418"},{"key":"71452_CR54","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet 45, 970\u2013976 (2013).","journal-title":"Nat. Genet"},{"key":"71452_CR55","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"71452_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13029-016-0060-z","volume":"11","author":"M Riester","year":"2016","unstructured":"Riester, M. et al. PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code Biol. Med. 11, 13 (2016).","journal-title":"Source Code Biol. Med"},{"key":"71452_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"71452_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"71452_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"71452_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. methods 14, 417\u2013419 (2017).","journal-title":"Nat. methods"},{"key":"71452_CR61","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 4, 1521 (2015).","journal-title":"F1000Res"},{"key":"71452_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"71452_CR63","doi-asserted-by":"publisher","unstructured":"Korotkevich G. et al. Fast gene set enrichment analysis. bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"71452_CR64","doi-asserted-by":"publisher","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","volume":"39","author":"D Croft","year":"2011","unstructured":"Croft, D. et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 39, D691\u2013D697 (2011).","journal-title":"Nucleic Acids Res"},{"key":"71452_CR65","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamaoncol.2023.7304","volume":"10","author":"A Fernandez-Martinez","year":"2024","unstructured":"Fernandez-Martinez, A. et al. Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. JAMA Oncol. 10, 603\u2013611 (2024).","journal-title":"JAMA Oncol."},{"key":"71452_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqaf131","volume":"7","author":"Q Yang","year":"2025","unstructured":"Yang, Q., Hartman, J. & Sifakis, E. G. BreastSubtypeR: a unified R\/Bioconductor package for intrinsic molecular subtyping in breast cancer research. NAR Genom. Bioinform 7, lqaf131 (2025).","journal-title":"NAR Genom. Bioinform"},{"key":"71452_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0520-4","volume":"17","author":"X Zhao","year":"2015","unstructured":"Zhao, X., Rodland, E. A., Tibshirani, R. & Plevritis, S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. 17, 29 (2015).","journal-title":"Breast Cancer Res"},{"key":"71452_CR68","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"71452_CR69","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-07-4756","volume":"14","author":"C Desmedt","year":"2008","unstructured":"Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158\u20135165 (2008).","journal-title":"Clin. Cancer Res"},{"key":"71452_CR70","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.  N. Engl. J. Med. 351, 2817\u20132826 (2004).","journal-title":"N. Engl. J. Med."},{"key":"71452_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0111-0","volume":"5","author":"BV Sinn","year":"2019","unstructured":"Sinn, B. V. et al. SET(ER\/PR): a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer 5, 16 (2019).","journal-title":"NPJ Breast Cancer"},{"key":"71452_CR72","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017).","journal-title":"Cell Rep."},{"key":"71452_CR73","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"71452_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"71452_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-4-3","volume":"4","author":"C Fan","year":"2011","unstructured":"Fan, C. et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genom. 4, 3 (2011).","journal-title":"BMC Med Genom."},{"key":"71452_CR76","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"71452_CR77","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ijc.32982","volume":"147","author":"R Tokunaga","year":"2020","unstructured":"Tokunaga, R. et al. 12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. Int J. Cancer 147, 532\u2013541 (2020).","journal-title":"Int J. Cancer"},{"key":"71452_CR78","doi-asserted-by":"publisher","first-page":"68012","DOI":"10.18632\/oncotarget.12010","volume":"7","author":"L Malorni","year":"2016","unstructured":"Malorni, L. et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget 7, 68012\u201368022 (2016).","journal-title":"Oncotarget"},{"key":"71452_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7500 samples. Genome Biol. 15, 431 (2014).","journal-title":"Genome Biol."},{"key":"71452_CR80","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399\u2013404 (2019).","journal-title":"Nature"},{"key":"71452_CR81","doi-asserted-by":"publisher","first-page":"8852","DOI":"10.1158\/0008-5472.CAN-10-1039","volume":"70","author":"G Bianchini","year":"2010","unstructured":"Bianchini, G. et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res. 70, 8852\u20138862 (2010).","journal-title":"Cancer Res"},{"key":"71452_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00465-3","volume":"8","author":"J Staaf","year":"2022","unstructured":"Staaf, J. et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer 8, 94 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"71452_CR83","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","volume":"23","author":"LV Rubinstein","year":"2005","unstructured":"Rubinstein, L. V. et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 23, 7199\u20137206 (2005).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71452-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71452-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71452-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:02:14Z","timestamp":1775797334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71452-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71452"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71452-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.: speaker (no personal fees): Roche, Seagen; consultant (no personal or institutional fees): Roche, AstraZeneca, Veracyte; research funding paid to institution by Merck, AstraZeneca, Novartis, Veracyte; advisory board: Nordic Pharma (no personal or institutional fees). I.Z.: institutional research grants from Gilead and honoraria paid to his institution from Novartis. J.H.: Leadership and ownership interests in Stratipath AB. Speaker: Gilead. Honoraria from MSD, Pfizer, Lilly. Research funding (paid to institution): Novartis, Cepheid. G.V.: speaker\u2019s fee from Pfizer, MSD, GSK and Pierre Fabre; advisory role with AstraZeneca; consultant fees from Reveal Genomics. T.P.: speaker\u2019s fee from Pfizer, AstraZeneca, Novartis, Veracyte and Argenetics; advisory role with Novartis. J.B.: research funding to institution (Karolinska Institutet and\/or Karolinska University Hospital) from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche and Sanofi; honoraria from UpToDate paid to Asklepios Medicin HB; head of advisory board at Stratipath AB; Coronis and Asklepios Cancer Research AB hold shares of Stratipath AB; honoraria for lectures\/educational conferences for postgraduates courses from AstraZeneca paid to Coronis and Asklepios Cancer Research AB, chairmanship for meetings arranged by Akademikonferens on behalf of Roche, and a lecture for Novartis, honoraria to Coronis and Asklepios Cancer Research AB for both activities. T.F.: institutional fees for consultancy to AstraZeneca, Gilead and Roche; personal fees for consultancy to Affibody, Pfizer, Novartis, Veracyte, Exact Sciences; honoraria from UpToDate; research funding to institution from Pfizer, AstraZeneca, Novartis and Veracyte. All the other authors had no potential conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3403"}}